Alessio Aghemo

Summary

Affiliation: Ospedale Maggiore
Country: Italy

Publications

  1. doi request reprint Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C
    Alessio Aghemo
    First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Italy
    Hepatology 56:1681-7. 2012
  2. pmc Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection
    Alessio Aghemo
    Angela Maria e Antonio Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
    Hepat Mon 12:411-4. 2012
  3. pmc Treatment of patients with HCV related cirrhosis: many rewards with very few risks
    Roberta D'Ambrosio
    First Division of Gastroenterology, Cà Granda Hospital Foundation IRCCS Maggiore Policlinico, University of Milan, Milan, Italy
    Hepat Mon 12:361-8. 2012
  4. pmc Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients
    Alessio Aghemo
    Centro AM e A Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Universita degli Studi di Milano, Milano, Italy
    Biomed Res Int 2013:580796. 2013
  5. doi request reprint Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C
    Alessio Aghemo
    AM and A Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS, Maggiore Hospital, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Expert Rev Anti Infect Ther 7:925-35. 2009
  6. doi request reprint Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
  7. doi request reprint Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4
    Stella De Nicola
    Centro AM e A Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Universita degli Studi di Milano, Milan, Italy
    Hepatology 55:336-42. 2012
  8. ncbi request reprint Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study
    Maria Grazia Rumi
    AM Et A Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 12:1033-40. 2007
  9. ncbi request reprint The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype
    Alessio Aghemo
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 14:577-84. 2009
  10. ncbi request reprint The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
    Roberta D'Ambrosio
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Antivir Ther 16:677-84. 2011

Collaborators

Detail Information

Publications45

  1. doi request reprint Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C
    Alessio Aghemo
    First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Italy
    Hepatology 56:1681-7. 2012
    ..81, 95% confidence interval = 1.39-5.67, P = 0.004) and a 10% body mass index increase (odds ratio = 6.42, 95% confidence interval = 1.69-24.3, P = 0.006) were significantly associated with the development of de novo IR...
  2. pmc Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection
    Alessio Aghemo
    Angela Maria e Antonio Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
    Hepat Mon 12:411-4. 2012
    ..Based on these findings, we decided to offer such a therapy to a 65 year old woman on the oLT list...
  3. pmc Treatment of patients with HCV related cirrhosis: many rewards with very few risks
    Roberta D'Ambrosio
    First Division of Gastroenterology, Cà Granda Hospital Foundation IRCCS Maggiore Policlinico, University of Milan, Milan, Italy
    Hepat Mon 12:361-8. 2012
    ..For this reason regimens able to clear the virus without relying on the broad antiviral effect of IFN are eagerly awaited...
  4. pmc Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients
    Alessio Aghemo
    Centro AM e A Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Universita degli Studi di Milano, Milano, Italy
    Biomed Res Int 2013:580796. 2013
    ..The impact of baseline predictors of treatment outcome and their interplay with viral kinetics in HCV-1 CC patients has not been fully evaluated...
  5. doi request reprint Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C
    Alessio Aghemo
    AM and A Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS, Maggiore Hospital, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Expert Rev Anti Infect Ther 7:925-35. 2009
    ..Currently, two forms of pegylated IFN exist (alpha2a and alpha2b), which differ significantly in terms of pharmacokinetics and dynamics, is whether these peculiarities translate into different efficacy rates being still being debated...
  6. doi request reprint Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens...
  7. doi request reprint Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4
    Stella De Nicola
    Centro AM e A Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Universita degli Studi di Milano, Milan, Italy
    Hepatology 55:336-42. 2012
    ..001). By logistic regression, the IL28B rs12979860 CC genotype was an independent predictor of SVR with an odds ratio of 8.0 (95% confidence interval 2.00-32.01; P = 0.003)...
  8. ncbi request reprint Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study
    Maria Grazia Rumi
    AM Et A Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 12:1033-40. 2007
    ..The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators...
  9. ncbi request reprint The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype
    Alessio Aghemo
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 14:577-84. 2009
    ..We aimed to assess whether cirrhosis modifies the pattern of PEG-IFN-alpha2b and RBV treatment failure...
  10. ncbi request reprint The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
    Roberta D'Ambrosio
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Antivir Ther 16:677-84. 2011
    ..Our aim was to prospectively assess whether a successful IFN therapy modifies development and/or progression of EV in patients with HCV-related compensated cirrhosis...
  11. ncbi request reprint Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection
    Alessio Aghemo
    A M Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 11:797-802. 2006
    ..Evaluation of liver fibrosis is important in the management of patients with genotype 3a hepatitis C, since it helps to predict response to IFN/RBV therapy...
  12. doi request reprint Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis
    Gian Maria Prati
    A M Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    J Hepatol 56:341-7. 2012
    ..Whether fibrosis equally affects the two PegIFNα-based therapies is unknown. To assess the response to the two PegIFN regimens in patients with different degree of liver fibrosis...
  13. doi request reprint PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history
    Elisabetta Degasperi
    Department of Medicine, A M Migliavacca Center for Liver Diseases and First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Expert Rev Anti Infect Ther 11:459-74. 2013
    ..However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment...
  14. doi request reprint Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis
    Massimo Iavarone
    Centro AM e A Migliavacca for Liver Diseases, 1st Division of Gastroenterology, Fondazione IRCCS Ca Granda Maggiore Hospital, University of Milan, Italy
    Dig Liver Dis 45:43-9. 2013
    ..A better understanding of the relationships between dysplastic nodules and hepatocellular carcinoma development may help refining strategies of enhanced follow-up...
  15. doi request reprint How to optimize HCV therapy in genotype 2 patients
    Eleonora Grassi
    A M and A Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Liver Int 33:35-40. 2013
    ..On the other hand, patients who do not achieve a RVR correspond to a population of difficult-to-cure HCV-2 patients who need alternative treatment strategies which are not yet available...
  16. ncbi request reprint The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin
    Mauro Vigano
    Angela Maria and Antonio Migliavacca Center for Liver Disease, First Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 14:789-96. 2009
    ..Those who are coinfected with hepatitis B virus (HBV), however, might suffer from HBV reactivation. The aim of this study was to assess HBV reactivation in HCV-coinfected inactive HBV carriers following IFN/RBV...
  17. doi request reprint Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C
    Alessio Aghemo
    A M Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Via F Sforza 35, 20122 Milan, Italy
    Nat Rev Gastroenterol Hepatol 7:485-94. 2010
    ..We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-alpha2a and PEG-IFN-alpha2b...
  18. doi request reprint Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
    Francesco Marabita
    Istituto Nazionale Genetica Molecolare, Milano, Italy
    Hepatology 54:1127-34. 2011
    ..Male gender (P < 0.05), HCV genotype 3 (P < 0.001) and steatosis (P < 0.05) were also associated with faster fibrosis progression. Conversely, the two IL28B polymorphisms had no impact on fibrosis progression...
  19. doi request reprint The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response
    Roberta D'Ambrosio
    A M and A Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    J Hepatol 59:251-6. 2013
    ..Whether TE may sense changes of liver fibrosis following therapeutic HCV eradication has never been evaluated...
  20. pmc The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent
    Roberta D'Ambrosio
    Division of Gastroenterology and Hepatology, Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan 20100, Italy
    Int J Mol Sci 15:7213-24. 2014
    ..IL28B genotype was CC in 117 (34%), CT in 166 (49%) and TT in 52 (15%). At univariate analysis, the IL28B CC genotype was associated with severe portal inflammation in HCV-1 patients (CC vs...
  21. ncbi request reprint The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies
    Valentina Monti
    A M Et A Migliavacca Center for Liver Disease, Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital Fondazione Policlinico, Mangiagalli, Regina Elena and University of Milan, Milan, Italy
    Antivir Ther 10:715-20. 2005
    ..Whether interferon/ribavirin therapy is safe and effective in these patients is unclear...
  22. doi request reprint Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma
    Armando Tripodi
    Department of Internal Medicine and Medical Specialties, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Via Pace 9, 20122, Milan, Italy
    Intern Emerg Med 7:139-44. 2012
    ..These results question the validity of the PT as a stand-alone test to guide transfusion of FFP in the setting of chronic liver disease...
  23. doi request reprint Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis
    Bernardo Dell'Osso
    Department of Psychiatry, Fondazione IRCSS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    J Interferon Cytokine Res 33:9-14. 2013
    ..Further investigation is warranted to confirm results...
  24. doi request reprint A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
    Roberta D'Ambrosio
    A M and A Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Hepatology 56:532-43. 2012
    ..41) and αSMA (P = 0.95). Finally, no differences in all the immunohistochemical scores emerged whether or not cirrhosis persisted...
  25. doi request reprint A review of the treatment of chronic hepatitis C virus infection in cirrhosis
    Elena Vezali
    Centro A M e A Migliavacca, Unità Operativa di Gastroenterologia 1, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Clin Ther 32:2117-38. 2010
    ..Cirrhosis developing during chronic infection with the hepatitis C virus (HCV) poses a risk of anticipated liver-related death, therefore representing a dominant indication to anti-HCV therapy...
  26. pmc Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir
    Alessio Aghemo
    A M and A Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    PLoS ONE 9:e95881. 2014
    ..Inosine triphosphatase (ITPA) genetic variants are associated with RBV- induced anemia and dose reduction...
  27. doi request reprint Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside
    Alessio Aghemo
    AM e A Migliavacca Center for Liver Disease, Department of Medicine, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Semin Immunopathol 35:111-20. 2013
    ..Moreover, a successful antiviral treatment has the added benefit of positively impacting on the rate of HCC development also in patients who are already cirrhotic...
  28. pmc Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies
    Cristina Della Corte
    AM Migliavacca Center for Liver Diseases, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, 20122 Milan, Italy
    World J Gastroenterol 19:1359-71. 2013
    ..This could finally pave the way to personalized algorithms, as already seen in the diagnosis and treatment schemes for chemoprevention...
  29. doi request reprint Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management
    Mauro Vigano
    San Giuseppe Hospital, Hepatology Unit, Milan, Italy
    Expert Opin Biol Ther 12:193-207. 2012
    ..Since TNF-α is a mediator of the immune response against viral infections, use of TNF-α inhibitors in patients with concurrent HBV or HCV infection can promote viral reactivation and potentially fatal liver failure...
  30. pmc Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
    Alessio Aghemo
    A M Migliavacca Center for Liver Disease First, Division of Gastroenterology, IRCCS Fondazione Ca Granda Hospital, University of Milan, Milan, Italy
    Hepat Mon 11:918-24. 2011
    ..Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment...
  31. doi request reprint Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation
    Alessandra Dell'Era
    Department of Medical Sciences, Università degli Studi di Milano IRCCS Fondazione Cà Granda Ospedale Policlinico di Milano, Milan, Italy Gastroenterology 3 Unit IRCCS Fondazione Cà Granda Ospedale Policlinico di Milano, Milan, Italy Electronic address
    Dig Liver Dis 46:152-6. 2014
    ..Aim of the study was to assess influence of thrombosis on rate and time to eradication in cirrhosis and extrahepatic portal vein obstruction undergoing banding, compared to cirrhotic patients without thrombosis...
  32. doi request reprint Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials
    Alessio Aghemo
    Department of Medicine, AM Migliavacca Center for Liver Diseases and First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Dig Liver Dis 45:1-7. 2013
    ....
  33. doi request reprint Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?
    Elena Vezali
    Centro A M e A Migliavacca, Unità Operativa di Gastroenterologia 1, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milano, Italy
    Clin Res Hepatol Gastroenterol 35:455-64. 2011
    ....
  34. doi request reprint Interferon in the treatment of chronic hepatitis C: a drug caught between past and future
    Elena Vezali
    A M Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Via F Sforza 35, 20122 Milan, Italy
    Expert Opin Biol Ther 11:301-13. 2011
    ..Research is focussed on the directly acting antivirals, such as telaprevir and boceprevir, which are anticipated to enter the drug market during the next few years...
  35. doi request reprint Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method
    Armando Tripodi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, Universita degli Studi di Milano, Milan, Italy
    Hepatology 52:249-55. 2010
    ..59). The PICI% values were correlated with the levels of protein C (rho = 0.728, P < 0.001) or factor VIII (rho = -0.517, P < 0.001). Finally, the PICI% values were correlated with the predicate assay (rho = -0.580, P < 0.001)...
  36. doi request reprint Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione IRCCS Ospedale Maggiore Policlinico Ca Granda IRCCS, Milan, Italy
    Hepatology 53:791-9. 2011
    ..47, 95% CI 1.2-1.9; P = 0.002), treatment response (n = 470; OR 0.63, 95% CI 0.4-0.8; P = 0.006), and HCC occurrence (n = 325; OR 2.16, 95% CI 1.3-3.6; P = 0.002), independently of confounders...
  37. doi request reprint Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense
    Alessio Aghemo
    Department of Medicine, A M Migliavacca Center for Liver Diseases and First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    J Hepatol 57:1326-35. 2012
    ..However, it also calls for demonstration that surrogate end points in the treatment of patients with chronic hepatitis B or C are good and reliable markers of long-term efficacy...
  38. ncbi request reprint Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review
    Fabrizio Fabrizi
    Division of Nephrology, Maggiore Policlinico Hospital, IRCCS Foundation, Milan, Italy
    Kidney Blood Press Res 38:52-60. 2013
    ..Interferon treatment of malignant or viral diseases can be accompanied by various side-effects including nephro-toxicity...
  39. doi request reprint Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation
    Massimo Iavarone
    1st Division of Gastroenterology, Center for Liver Diseases, Milan, Italy
    Hepatology 52:1723-30. 2010
    ..01). Among 1- to 2-cm tumors, the radiological diagnosis was achieved in two of 16 grade I and 17 of 31 grade II-III tumors (P = 0.006)...
  40. pmc HBV and HCV therapy
    Pietro Lampertico
    A M Migliavacca Center for Liver Disease, First Gastroenterology Unit, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita di Milano, Via F Sforza 35, 20122 Milan, Italy
    Viruses 1:484-509. 2009
    ..Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation...
  41. ncbi request reprint Hepatitis C treatment in patients with kidney disease
    Fabrizio Fabrizi
    Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy
    Kidney Int 84:874-9. 2013
    ..Current guidelines support monotherapy with standard interferon in these patients, but modern antiviral approaches (that is, dual therapy with peg-IFN plus ribavirin) in a well-controlled setting may be an appropriate alternative. ..
  42. doi request reprint Hepatorenal syndrome and novel advances in its management
    Fabrizio Fabrizi
    Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy
    Kidney Blood Press Res 37:588-601. 2013
    ..Renal replacement therapy should not be considered a first-line therapy for HRS Clinical trials are under way in order to assess efficacy and safety of novel therapeutic agents for the treatment of type-1 and type-2 HRS...
  43. pmc Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
    Roberta D'Ambrosio
    Centro A M e A Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Biologics 6:363-70. 2012
    ....
  44. ncbi request reprint Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens
    Alessio Aghemo
    First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    J Hepatol 56:276-8. 2012
    ..Gastroenterology. 2011;140:840-9. Copyright (2011). Abstract reprinted with permission from the American Gastroenterological Association. http://www.ncbi.nlm.nih.gov/pubmed/21129375 ABSTRACT:..
  45. doi request reprint High levels of factor VIII and risk of extra-hepatic portal vein obstruction
    Ida Martinelli
    Department of Internal Medicine and Medical Specialties, A Bianchi Bonomi Hemophilia and Thrombosis Center and Gastroenterology Unit, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
    J Hepatol 50:916-22. 2009
    ..High levels of coagulation factor VIII are a risk factor for lower-limb deep vein thrombosis (DVT). Their role in extra-hepatic portal vein obstruction (EHPVO) is not established...